Small molecule cancer drug developer Metabomed raised the cash from investors including Pfizer, Boehringer Ingelheim and co-founder MS Ventures.

Israel-based cancer metabolism startup Metabomed closed an $18m series A round on Monday that included founding partner MS Ventures, a subsidiary of Germany-based pharmaceutical company Merck Group.

The round was completed after pharmaceutical firm Pfizer and investment fund Arkin Holdings joined existing backers MS Ventures, Boehringer Ingelheim Venture Fund, which acts as pharmaceutical company Boehringer Ingelheim’s corporate venturing unit, Pontifax and Technion Research and Development Foundation.

Co-founded by MS Ventures’ Israel BioIncubator and three cancer metabolism and computational biology researchers,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?